



## Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference

May 2, 2018

MONROVIA, Calif., May 2, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Deutsche Bank 43<sup>rd</sup> Annual Health Care Conference on Wednesday, May 9, 2018 at 9:20 a.m. ET in Boston, MA.



A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at [www.xencor.com](http://www.xencor.com). A replay of the presentation will be posted on the Xencor website approximately one hour after the live event and will be available for 90 days following the presentation.

### **About Xencor, Inc.**

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 11 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb@5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb@7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb@14045 in Phase 1 development for acute myeloid leukemia; XmAb@13676 in Phase 1 development for B-cell malignancies; XmAb@18087 in Phase 1 development for the treatment of neuroendocrine tumors and gastrointestinal stromal tumors; and XmAb@20717, XmAb@22841, XmAb@23104 and XmAb@24306 in pre-clinical development for the treatment of multiple cancers. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, CSL/Janssen, Alexion and Boehringer Ingelheim. For more information, please visit [www.xencor.com](http://www.xencor.com).

 View original content with multimedia: <http://www.prnewswire.com/news-releases/xencor-to-present-at-deutsche-bank-43rd-annual-health-care-conference-300631608.html>

SOURCE Xencor, Inc.

Investor, John Kuch, Vice President Finance, Xencor, Tel: 626-737-8013, [jkuch@xencor.com](mailto:jkuch@xencor.com), or Corporate Communications, Jason I. Spark, Canale Communications for Xencor, Tel: 619-849-6005, [jason@canalecomm.com](mailto:jason@canalecomm.com)